Another putative PARP1 inhibitor, Iniparib (Sanofi-Aventis) was reported to be a non-competitive inhibitor that made it through Phase I and Phase II clinical trials for breast cancer, but it eventually failed a Phase III trial [72,73]. Here, PARP1 is linked to breast carcinoma.